UOB Thailand to offer 10year subordinated notes callable after five years

Listen to this story

UOB Thailand plans to issue subordinated notes, in accordance with Basel III guidelines for Tier 2 capital. The notes will be offered to institutional and high-net-worth investors with a minimum subscription of THB 100,000.

The notes have a tenor of 10 years and are first callable at the option of the Bank five years from the issue date. The notes will bear a fixed coupon rate of 4.07 per cent. per annum, and coupon payment will be made every three months. Being subordinated notes of the Bank, they may be written off in whole or in part if the Bank is determined by the Bank of Thailand to be non-viable. 

Mr Sanchai Apisaksirikul, Managing Director, Country Head of Finance and Corporate Real Estate Services, UOB Thailand, said, “The subordinated notes Tier 2 issuance will further strengthen the Bank’s capital and support business growth. In addition, the notes will be additional investment options for investors.”

Investors can subscribe for the notes from 27 May to 6 June 2022 (during the Bank’s operating hours) at all UOB Thailand branches and two other leading financial institutions – Bangkok Bank and KASIKORNNBANK. For further information on the notes, including potential risks, investors may access the link to the Prospectus here or contact the following:

  • United Overseas Bank (Thai) Public Company Limited Tel. 02-093-4900 and 02-343-4900 
  • Bangkok Bank Public Company Limited Tel. 02-645-5555 or 1333 

·       KASIKORNBANK Public Company Limited Tel. 02-888-8888 press 819

UOB Thailand is a subsidiary of Singapore’s United Overseas Bank Limited, a leading regional bank and one of the highest rated banks globally. UOB Thailand has a highest rating of AAA(tha) for National Long-Term Rating with a stable outlook, and the subordinated notes have been rated AA(tha), by Fitch Ratings (Thailand).

This is a sponsored post

COVID-19

Ivermectin not effective in treating Covid-19, joint Mahidol-Oxford study shows

Ivermectin is not shown to be effective against Covid-19 in clinical trials according to the findings of a joint...

Latest article